Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Stock Information for Actinium Pharmaceuticals Inc. (Delaware)
Loading
Please wait while we load your information from QuoteMedia.